SQP, INC. v. Sirrom Sales, Inc.

130 F. Supp. 2d 364, 2001 U.S. Dist. LEXIS 1330, 2001 WL 135444
CourtDistrict Court, N.D. New York
DecidedFebruary 14, 2001
Docket1:00-cv-01781
StatusPublished
Cited by4 cases

This text of 130 F. Supp. 2d 364 (SQP, INC. v. Sirrom Sales, Inc.) is published on Counsel Stack Legal Research, covering District Court, N.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
SQP, INC. v. Sirrom Sales, Inc., 130 F. Supp. 2d 364, 2001 U.S. Dist. LEXIS 1330, 2001 WL 135444 (N.D.N.Y. 2001).

Opinion

MEMORANDUM-DECISION and ORDER

HURD, District Judge.

I. INTRODUCTION

Plaintiff SQP, Inc. (“SQP” or “plaintiff’) filed the instant suit alleging trademark infringement by defendants Sirrom Sales, Inc. and Morcon, Inc. (collectively “Mor-con” or “defendants”) and seeking redress for such infringement pursuant to the Lan-ham Act, 15 U.S.C. § 1125, common law, and New York General Business Law §§ 349-350. In essence, SQP alleges that Morcon has falsely advertised that its brand of toilet tissue is equivalent to SQP’s brand of toilet tissue, when the sheet counts of Morcon’s toilet tissue are lower. Morcon answered and asserted similar Lanham Act, common law, and state law counterclaims against plaintiff.

On November 22, 2000, an Order to Show Cause issued temporarily restraining defendants from directly or indirectly advertising that their toilet tissue product known alternatively as “Morsoft®,” “Millennium® Bath Tissue” or “Morsoft/Mil-lennium® Bath Tissue” (collectively “Millennium”) is the equivalent of plaintiffs Valay® bath tissue (“Valay”). No bond or other security was required for the issuance of the temporary restraining order. The Order to Show Cause further directed defendants to show cause why a preliminary injunction should not issue enjoining defendants from advertising equivalence; requiring defendants to alter their advert tising to report an accurate sheet count for their toilet tissue products; requiring defendants to notify any person or entity who previously received an advertisement or solicitation claiming equivalence between Millennium and Valay, of the actual sheet count of Millennium and the fact of non-equivalence to Valay with respect to sheet count; and directing defendants to pay plaintiffs costs and attorneys fees associated with obtaining the aforementioned relief. Defendants filed responsive papers, to which plaintiff replied.

Oral argument was heard on January 29, 2001, in Utica, New York, with the attorneys for the parties participating by video conference from Albany, New York. Decision was reserved and the temporary restraining order was left in effect pending further order of the court. Moreover, the plaintiff, upon its consent, was directed to refrain from mentioning to customers in any manner the temporary restraining order.

II. FACTS

SQP is a manufacturer of toilet tissue for industrial, commercial and institutional use nationwide. SQP manufactures Valay in 1-ply, 2500 sheet rolls and 2-ply, 1250 sheet rolls. SQP contends that sheet count is arguably the single-most important characteristic to purchasers of commercial toilet tissue. Consequently, SQP asserts that it maintains an extensive quality monitoring program to assure that the average sheet count of each roll produced and sold is within 1.5% of the advertised count.

In approximately July 2000, Morcon began production of 1-ply, 2500 sheet rolls and 2-ply, 1250 sheet rolls of toilet tissue. Morcon’s Millennium was in direct market competition to SQP’s Valay. During the initial introduction of Millennium into the marketplace, Morcon admittedly gave away as samples some rolls that contained fewer sheets than advertised (that is, fewer than 2500 and 1250 sheets, respectively)-

Soon after Morcon entered the commercial toilet tissue market, SQP became aware of this new competition. SQP came into possession of a letter dated September 12, 2000, that stated in relevant part that Morcon was in production “of the equivalent to the Valay bath tissue.” (See Compl. Ex. B.) The September 12, 2000, *366 letter referenced availability of Millennium 1-ply, 2500 count and 2-ply, 1250 count rolls and their prices, and offered samples if needed. According to Laura L. Morris, the Treasurer of both defendants, the September 12, 2000, letter was sent to one and only one of its customers, one Barry Goldman. (Morris Aff. ¶ 11-12.) Morcon sent one additional letter to one distributor in which Millennium was touted as “equivalent” to Valay, and did not make equivalence claims in any other manner. Id. ¶ 15. However, Morcon offered to sell Millennium in response to invitations for bids for “Valay-equivalent” toilet tissue.

Morcon asserts that it marketed Millennium as comparable or similar to Valay, but did not intend the use of the word equivalent to mean “exactly the same.” Essentially Morcon posits that it was and is selling Millennium as a substitute for or alternative to Valay to be used in Valay dispensers.

On December 6, 2000, SQP sent a letter to its customers noting that a Temporary Restraining Order had been granted against Morcon, listing sheet counts from its tests of Millennium, and indicating that it would protect its products from false and misleading advertising and non-equivalent knock-off products. (Ans.Ex. B.)

SQP obtained some rolls of Millennium and undertook testing of those rolls. SQP retained an independent testing laboratory and a statistician to evaluate the sheet counts of Millennium. According to SQP’s experts, whose testimony was proffered via affidavit, Millennium rolls consistently fall below 2500 and 1250 sheet counts, while Valay consistently meets the optimum 2500 and 1250 sheets per roll. The SQP results are described in more detail below.

Morcon also tested both its Millennium and SQP’s Valay. Contrary to the findings set forth by SQP, Morcon sets forth, via its expert’s affidavit, testing results showing that Millennium consistently meets its advertised sheet counts, whereas Valay rolls consistently contain fewer sheets than advertised. The determinations made by Morcon’s expert are also more fully described below.

III. DISCUSSION

A. Preliminary Injunction Standard/False Advertising Claim

A preliminary injunction should issue only where the party seeking such relief shows “that it is likely to suffer irreparable injury if relief is denied [and] also that there is either (1) a likelihood of success on the merits or (2) sufficiently serious questions going to the merits to make them a fair ground for litigation, with a balance of hardships tipping decidedly in the [movant’s] favor.” Procter & Gamble Co. v. Chesebrough-Pond’s Inc., 747 F.2d 114, 118 (2d Cir.1984); Otokoyama Co. v. Wine of Japan Import, Inc., 175 F.3d 266, 270 (2d Cir.1999). In order to succeed on the merits of a false advertising claim under the Lanham Act, a party must show either literal falsity of the advertising under scrutiny or that the advertising is literally true but likely to mislead or confuse. 1 Johnson & Johnson * Merck Consumer Pharm. Co. v. Smithkline Beecham Corp., 960 F.2d 294, 297 (2d Cir.1992).

Thus, in order to establish a likelihood of success on the merits on an application for a preliminary injunction, a party *367

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Perlot v. Green
D. Idaho, 2022
Procter & Gamble Co. v. Ultreo, Inc.
574 F. Supp. 2d 339 (S.D. New York, 2008)

Cite This Page — Counsel Stack

Bluebook (online)
130 F. Supp. 2d 364, 2001 U.S. Dist. LEXIS 1330, 2001 WL 135444, Counsel Stack Legal Research, https://law.counselstack.com/opinion/sqp-inc-v-sirrom-sales-inc-nynd-2001.